Longitude Capital
Finance · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2740 Sand Hill Rd Fl 2, Menlo Park, Cali...Phone Number
(650) 854-5700Website
www.longitudecapital.comRevenue
$5.2 MillionIndustry
About Longitude Capital
Longitude Capital Org Chart
Is Longitude Capital your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Longitude Capital launches new products
Earning: See what the market has to say on Longitude Capital recently announced quarterly report
Click to see if Longitude Capital had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Longitude Capital has new funding data
Website visits: Recent activity has been detected on your website
Check out if Longitude Capital is spiking on competitors!
Longitude Capital, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Longitude Capital has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Longitude Capital
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Longitude Capital
Compare insights from companies similar to Longitude Capital, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Longitude Capital is experiencing very low activity levels compared to other companies in the Finance sector.
What does this means?
Longitude Capital is drawing exceptional interest within the Finance industry, suggesting notable developments or strong market momentum, learn more about Longitude Capital.
Longitude Capital Tech Stack
A closer look at the technologies used by Longitude Capital
Most Recent Scoops
Longitude Capital News & Media
FIRE1 Secures $120M Financing
FIRE1, a Dublin, Ireland-based connected medical device solutions company, raised $120M in funding. The round was led by Polaris Partners and Elevage Medical Technologies, joined by new investors Sands Capital and Longitude Capital, and existing investors Andera Partners, Gilde Healthcare, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, NEA (New Enterprise Associates), Novo Holdings, […] The post FIRE1 Secures $120M Financing appeared first on FinSMEs.Kestra Medical Technologies Raises $196M in Funding
Kestra Medical Technologies, a Kirkland, WA-based wearable medical device and digital healthcare company, raised $196M in funding. The round was led by Andera Partners, Ally Bridge Group, Longitude Capital and Omega Funds with participation from new investors, funds and accounts advised by T. Rowe Price Investment Management, Inc., Eventide Asset Management, Gilmartin Capital, Bain Capital […] The post Kestra Medical Technologies Raises $196M in Funding appeared first on FinSMEs.Endogenex Raises $88M in Series C Financing
Endogenex, a Minneapolis, MN-based clinical-stage medical device company, raised $88M in Series C funding. Backers included Hatteras Venture Partners, Lumira Ventures, Orlando Health Ventures, Intuitive Ventures, Longitude Capital, Mayo Clinic, and Santé Ventures. The company intends to use the funds to complete the pivotal ReCET Clinical Study, which has been granted an Investigational Device Exemption […] The post Endogenex Raises $88M in Series C Financing appeared first on FinSMEs.Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease
SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics, LASN01, targeting interleukin-11 receptor (IL-11R) as a potential treatment for fibro-inflammatory diseases such as TED and IPF, and a highly potent, first-in-class monoclonal antibody, LASN500, targeting the interleukin-18 binding protein (IL-18BP) as a potential treatment for cancer, today announced the closing of an oversubscribed Series B financing which raised
Top Finance Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Longitude Capital
Longitude Capital is a healthcare focused venture capital firm that invests in biotechnology, medical technology and health solutions companies, pairing sector expertise, flexible capital and active partnership to help innovators scale and improve patient care.... Read More


